Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance

Abbott posts strong Q3 growth, tightens 2026 guidance, and launches multiple new products.

What the company is saying

Abbott reports third-quarter 2026 sales of $13,013 million, up 14.5% reported and 7.0% comparable, with GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.42. The company projects full-year 2026 comparable sales growth of approximately 6.0% and narrows its adjusted EPS guidance to $5.50–$5.55. Management highlights balanced growth across all major segments, citing double-digit increases in key Medical Devices sub-segments and sequential Nutrition sales growth of $118 million. Recent product launches and regulatory approvals—including Libre Duo, Amulet 360, TactiFlex Duo, and SimpleScreen CRC—are emphasized as innovation drivers. Chairman and CEO Robert B. Ford frames the results as evidence of a robust pipeline and sustainable growth potential. The announcement also underscores Abbott’s 411th consecutive quarterly dividend ($0.63/share) and its 54-year streak of dividend increases, reinforcing a message of stability and reliability.

What the data suggests

The disclosed numbers show strong top-line momentum, with third-quarter sales up 14.5% reported and 7.0% comparable, and all major business segments contributing to growth. Adjusted diluted EPS of $1.42 for Q3 supports the reaffirmed and tightened full-year guidance of $5.50–$5.55, indicating management’s confidence in sustained earnings. Segment data reveals Medical Devices sales of $5,826 million (+6.9% reported, +7.8% comparable), Diagnostics at $3,305 million (+46.7% reported, +6.4% comparable), Nutrition at $2,262 million (+5.1% reported, +4.9% comparable), and Established Pharmaceuticals at $1,614 million (+6.8% reported, +8.4% comparable). U.S. sales reached $5,504 million and international sales $7,509 million for the quarter. The company’s dividend record is intact, with a declared $0.63/share payout and 54 consecutive years of increases. While product-level and regional growth claims (e.g., 'world's first' sensor, double-digit India growth) are not fully quantified, the overall financial trajectory is positive and the disclosures are comprehensive at the consolidated and segment levels.

Analysis

Abbott's announcement is generally proportionate to its disclosed results, with strong realised sales and earnings growth, multiple product launches, and regulatory approvals. The majority of key claims are realised and supported by numerical data, including consolidated and segment-level sales, EPS, and dividend continuity. However, some operational claims (e.g., 'world's first' product, double-digit growth in sub-segments, and leadership in certain markets) are not fully substantiated with specific figures. The tone is positive but not excessively promotional, and forward-looking statements (guidance for full-year and Q4 2026) are reasonable in scope and timeframe. The recent acquisition of Exact Sciences is a large capital outlay, but its integration and earnings impact are not yet fully detailed, justifying the capital_intensity_flag. Overall, the gap between narrative and evidence is modest, with most claims grounded in disclosed facts, though some product and regional growth assertions lack granularity.

Risk flags

• ●Integration risk from the Exact Sciences acquisition is material, as the company must deliver on synergy and growth expectations following a large capital outlay. The announcement does not detail integration progress or specific financial impacts from this deal.
• ●Some highlighted growth drivers—such as double-digit gains in India, Electrophysiology, and product-level performance for Cologuard and Libre Duo—are not backed by specific sales figures, making it difficult to independently verify the magnitude of these contributions.
• ●Ongoing reliance on new product launches and regulatory approvals introduces execution risk, as commercial uptake and reimbursement for innovations like Libre Duo and SimpleScreen CRC are not guaranteed and could affect future growth.
• ●Foreign exchange and macroeconomic conditions remain a risk, particularly for international sales, as the company notes FX impacts in its segment reporting and guidance.
• ●While dividend continuity is a strength, maintaining a 54-year growth streak could constrain capital allocation flexibility if earnings growth slows or integration costs rise.

Bottom line

Abbott’s Q3 2026 update demonstrates robust sales and earnings growth, with strong performance across all major business segments and a tightened full-year outlook. The company’s narrative is credible at the consolidated and segment level, though some product and regional growth claims lack granular support. Dividend reliability and a record of 54 consecutive annual increases add to the investment case for income-focused holders. The integration of Exact Sciences and the commercial success of recent product launches are key areas to monitor for sustained momentum. Near-term catalysts include Q4 results and further clarity on acquisition benefits. The most important takeaway is that Abbott is executing well on its core businesses and innovation pipeline, but investors should track the real-world impact of new products and the integration of acquired assets.

Announcement summary

(NYSE:ABT) Abbott reported third-quarter 2026 sales of $13,013 million, representing a 14.5 percent increase on a reported basis and 7.0 percent on a comparable basis. Third-quarter GAAP diluted EPS was $0.53, and adjusted diluted EPS was $1.42, which excludes specified items. Abbott projects full-year 2026 comparable sales growth to be approximately 6.0 percent. The company reaffirmed and tightened its full-year 2026 adjusted diluted EPS guidance range to $5.50 to $5.55. In August 2026, Abbott received U.S. FDA approval for Libre® Duo, the world's first dual glucose-ketone biowearable sensor, and CE Mark for Amulet 360™ Left Atrial Appendage Occluder. Abbott also launched Similac® 360 Total Care® Made With Whole Milk in the United States and received FDA approval for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ in September. The company launched SimpleScreen™ CRC, an FDA-approved blood-based colorectal cancer screening test for adults age 45 and older. Third-quarter U.S. sales were $5,504 million and international sales were $7,509 million. Nutrition segment sales for the quarter were $2,262 million, Diagnostics $3,305 million, Established Pharmaceuticals $1,614 million, and Medical Devices $5,826 million. On a sequential basis, worldwide Nutrition sales increased $118 million compared to the second quarter of 2026. In Diagnostics, U.S. sales were $1,853 million and international sales were $1,452 million, with Cancer Diagnostics driven by Cologuard® and contributions from precision oncology and international businesses. Abbott completed the acquisition of Exact Sciences on March 23, 2026, with Exact Sciences' 2025 worldwide sales at $3,247 million. Established Pharmaceuticals sales in key emerging markets increased 9.0 percent on a reported basis and 10.9 percent on a comparable basis, led by double-digit growth in India. Medical Devices sales growth was led by double-digit increases in Electrophysiology and Rhythm Management, with Diabetes Care continuous glucose monitor sales up 7.3 percent reported and 7.7 percent comparable. For the first nine months of 2026, total company sales were $36,770 million, with U.S. sales of $14,994 million and international sales of $21,776 million. Abbott declared its 411th consecutive quarterly dividend of $0.63 per share, payable November 16, 2026, to shareholders of record as of October 15, 2026. Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index. In 2025, total worldwide sales were $44.328 billion, with U.S. sales of $17.126 billion and international sales of $27.202 billion. Abbott's Structural Heart business received $89 million of compensation payments in 2025 as part of a multi-year agreement with a competitor. The company projects fourth-quarter 2026 adjusted diluted EPS of $1.62 to $1.67.

Disagree with this article?